Research Topic

Our Vision

• To pioneer transformative therapies through the intelligent design and engineering of biomaterials and nanomedicines, aiming to revolutionize the way diseases are treated. Our vision is to integrate biotechnology, pharmaceutical science, and clinical insight to create safer, more effective, and patient-centered therapeutic solutions that address unmet medical needs and improve the quality of life for people around the world. 

A. Development of bio-responsive targeted nanoparticles

We engineer nanoparticles that respond to the disease microenvironment, enabling highly selective drug delivery and controlled release for enhanced therapeutic efficacy.

B. Reprogramming the tumor microenvironment

We investigate strategies to reprogram the tumor microenvironment (TME) to overcome drug resistance, enhance immunotherapy responses, and suppress cancer progression. By targeting key tumor-promoting features of the TME—such as transforming immunosuppressive M2 macrophages into anti-tumorigenic M1 macrophages or activating cytotoxic T cell or natural killer cells (NK) cells —we aim to shift the TME into a state that favors effective cancer treatment.

C. Development of antibody drug conjugates

Our team designs and develops novel ADCs that combine targeting specificity of antibodies with the potent activity of small-molecule drugs for precise cancer therapy

D. Development of Immune-Modulating Nanosystems

We design nanoscale platforms- both single-targeted and bispecific, that modulates the immune response to enhance antitumoral immunity and treat inflammatory diseases